What happened between Genetic Signatures and BCAL Diagnostics?

Genetic Signatures (ASX:GSS) received no advance notification regarding a 10.2% stake acquisition by BCAL Diagnostics (ASX:BDX). BCAL Diagnostics (ASX:BDX) purchased 23,173,644 shares in Genetic Signatures (ASX:GSS) at 6 cents each without holding prior strategic discussions.

How did the stock market react to the Genetic Signatures announcement?

The Genetic Signatures (ASX:GSS) share price fell 5.7% to 6.6 cents following the market update. This drop occurred immediately after the company confirmed it had no prior knowledge of the share purchase by BCAL Diagnostics (ASX:BDX).

What strategic proposals did BCAL Diagnostics make to Genetic Signatures?

Genetic Signatures (ASX:GSS) stated that it has received no approach, strategic proposal, or communication from BCAL Diagnostics (ASX:BDX) regarding any corporate transactions. The company is currently not in a position to comment on the intentions of BCAL Diagnostics (ASX:BDX).

How will this transaction impact the daily operations of Genetic Signatures?

The board of Genetic Signatures (ASX:GSS) stated that the business continues to operate normally despite the unannounced share acquisition by BCAL Diagnostics (ASX:BDX). The company remains focused on executing its existing commercial initiatives and financial objectives.

Health

Image for illustrative purposes only. Not a real photo.

Genetic Signatures responds to 10.2% BCAL Diagnostics stake

Written by Liezl GambePublished Jul 2, 2026, 6:04 AM

Genetic Signatures announced it had no prior knowledge of a recent acquisition of its shares by another diagnostics company.
The company's stock fell 5.7% to 6.6 cents following the market update.
Management stated that the business remains fully focused on executing its current operational and financial strategy.

Genetic Signatures (ASX:GSS) received no advance notification regarding a 10.2% stake acquisition by BCAL Diagnostics (ASX:BDX).

This unannounced share purchase contrasts with typical corporate transactions where investments are preceded by confidential strategic discussions.

The company received no strategic proposals following BCAL Diagnostics purchasing 23,173,644 shares at 6 cents each.

Following the announcement, the Genetic Signatures share price was down at $0.066.

The board reassured stakeholders that the business continues to operate normally while executing its commercial initiatives.

CEO Maria Halasz previously outlined these long-term financial objectives during a market presentation on June 10.

The company stated it will continue monitoring developments to ensure compliance with its continuous disclosure obligations.